Skip to main content
. 2026 Oct 17;18(10):1155. doi: 10.3390/v18101155
Ab antibody
ACIP Advisory Committee on Immunization Practices
AReSVi-006 phase 3 trial of RSVPreF3 in older adults
AS01 adjuvant system 01 (GlaxoSmithKline)
AS03 adjuvant system 03 (GlaxoSmithKline)
BA.1 SARS-CoV-2 Omicron sublineage BA.1
BA.2 SARS-CoV-2 Omicron sublineage BA.2
BA.2.86 SARS-CoV-2 Omicron sublineage BA.2.86
BA.4 SARS-CoV-2 Omicron sublineage BA.4
BA.5 SARS-CoV-2 Omicron sublineage BA.5
BCR B-cell receptor
bnAb(s) broadly neutralizing antibody(ies)
BNT162b2 Pfizer-BioNTech COVID-19 mRNA vaccine
CDC US Centers for Disease Control and Prevention
ChAdOx1 chimpanzee adenovirus Oxford 1 (viral vector)
CIDRAP Center for Infectious Disease Research and Policy
COBRA computationally optimized broadly reactive antigen
Com-COV Comparing COVID-19 Vaccine Schedule Combinations trial
Com-COV2 Comparing COVID-19 Vaccine Schedule Combinations trial 2
COVID-19 coronavirus disease 2019
cryo-EM cryogenic electron microscopy
F fusion protein (RSV surface glycoprotein)
FDA US Food and Drug Administration
FDC follicular dendritic cell
FI-RSV formalin-inactivated respiratory syncytial virus vaccine
G attachment glycoprotein (RSV surface protein)
GC(s) germinal center(s)
H1 hemagglutinin subtype 1
H1N1 influenza A hemagglutinin 1, neuraminidase 1
H2 hemagglutinin subtype 2
H2N2 influenza A hemagglutinin 2, neuraminidase 2
H3 hemagglutinin subtype 3
H3N2 influenza A hemagglutinin 3, neuraminidase 2
H5 hemagglutinin subtype 5
H5N1 influenza A hemagglutinin 5, neuraminidase 1
H7 hemagglutinin subtype 7
H7N9 influenza A hemagglutinin 7, neuraminidase 9
HA hemagglutinin
HAI hemagglutination inhibition
HARMONIE nirsevimab post-authorization real-world effectiveness study
IBV influenza B virus
IgG immunoglobulin G
IgM immunoglobulin M
JN.1 SARS-CoV-2 Omicron sublineage JN.1
KP.2 SARS-CoV-2 Omicron sublineage KP.2
KP.3 SARS-CoV-2 Omicron sublineage KP.3
LAIV live attenuated influenza vaccine
mAb(s) monoclonal antibody(ies)
MATISSE phase 3 trial of RSVpreF maternal vaccine
MELODY phase 3 trial of nirsevimab in healthy term and late-preterm infants
MERS-CoV Middle East respiratory syndrome coronavirus
MF59 squalene-based oil-in-water adjuvant
MMWR Morbidity and Mortality Weekly Report (US CDC)
mRNA messenger RNA
NA neuraminidase
NK natural killer (cell)
OAS original antigenic sin
post-F postfusion conformation of RSV F protein
pre-F prefusion conformation of RSV F protein
RBD receptor-binding domain (of SARS-CoV-2 spike)
RSV respiratory syncytial virus
RSV-A respiratory syncytial virus subgroup A
RSV-B respiratory syncytial virus subgroup B
RSVpreF bivalent RSV prefusion F vaccine (Pfizer, Abrysvo)
RSVPreF3 RSV prefusion F vaccine (GlaxoSmithKline, Arexvy)
S spike protein (of SARS-CoV-2)
S1 spike subunit 1
S2 spike subunit 2
S2P6 human monoclonal antibody targeting the conserved S2 stem
SARS severe acute respiratory syndrome
SARS-CoV severe acute respiratory syndrome coronavirus
SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
SHM somatic hypermutation
Tfh T follicular helper (cell)
Th1 T helper type 1
Th2 T helper type 2
UK United Kingdom
US United States
VE vaccine effectiveness
VLP virus-like particle
WHO World Health Organization
WT wild type
Wuhan-Hu-1 ancestral SARS-CoV-2 reference sequence
XBB SARS-CoV-2 recombinant Omicron lineage XBB
XBB.1.5 SARS-CoV-2 Omicron sublineage XBB.1.5
XEC SARS-CoV-2 Omicron recombinant sublineage XEC
ZOE-50 phase 3 trial of the adjuvanted zoster subunit vaccine